



| Country Demographics <sup>1, 2, 6</sup>                 |            |
|---|------------|
| Total Population (2020) <sup>6</sup>                    | 31,914,989 |
| Urban Population (% of total, 2020) <sup>6</sup>        | 78.3%      |
| Health expenditure per capita (\$US, 2017) <sup>1</sup> | \$332.57   |
| Health expenditure, total (% of GDP, 2017) <sup>1</sup> | 5.00%      |
| Total births (2013) <sup>2</sup>                        | 599,000    |
| Surviving Infants (2013) <sup>2</sup>                   | 589,000    |
| Life expectancy at birth (years, 2020) <sup>6</sup>     | 74.7 years |
| Number of districts (2013) <sup>2</sup>                 | 1838       |

| HBsAg Prevalence <sup>3</sup> |      |
|-------------------------------|------|
| Pre-vaccine HBsAG+ (%)        | 1.9% |

| Liver Cancer as Cause of Cancer Death (in Men) <sup>4</sup> |            |
|---|------------|
| Year: 2018  | Ranking: 5 |

| 2019 Country Comparison in Americas Region (35 Countries) <sup>5</sup> |      |  |   |                                 |
|--|------|--|---|---------------------------------|
|  | Peru | Number of countries with reported coverage | Highest reported coverage in AMR                  | Lowest reported coverage in AMR |
| HepB3 <sup>5</sup>   | 88%  | 35   | 99% (Antigua and Barbuda, Cuba, Dominica, Guyana) | 51% (Haiti)                     |
| HepB BD <sup>5</sup>   | 82%  | 22   | 99% (Cuba, Saint Vincent and the Grenadines)      | 48% (Guatemala)                 |

| Hepatitis B Immunization Coverage <sup>5</sup> |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
|--|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
|  | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| HepB3 <sup>5</sup>                             | NR   | NR   | NR   | 65%  | 92%  | 94%  | 94%  | 93%  | 93%  | 93%  | 93%  | 91%  | 95%  | 88%  | 88%  | 90%  | 89%  | 83%  | 84%  | 88%  |
| HepB BD <sup>5</sup>                           | NR   | NR   | NR   | 60%  | 68%  | 67%  | 66%  | 73%  | 79%  | 71%  | 74%  | 76%  | 81%  | 82%  | 78%  | 79%  | 79%  | 75%  | 73%  | 82%  |
| DTP3 <sup>5</sup>                              | 98%  | 90%  | 95%  | 94%  | 86%  | 77%  | 94%  | 93%  | 93%  | 93%  | 93%  | 91%  | 95%  | 88%  | 88%  | 90%  | 89%  | 83%  | 84%  | 88%  |
| BCG <sup>5</sup>                               | 93%  | 87%  | 92%  | 94%  | 95%  | 95%  | 96%  | 96%  | 97%  | 97%  | 95%  | 91%  | 95%  | 95%  | 94%  | 91%  | 90%  | 84%  | 81%  | 81%  |



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAG= HepB surface antigen. Data Compiled by Asian Liver Center at Stanford University 2019: World DataBank: World Development Indicators database<sup>1</sup>, WHO Immunization Summary: A statistical reference containing data through 2013<sup>2</sup>, WHO Public Health Significance, Targets, Strategies: HBV country profiles<sup>3</sup>, Global Cancer Observatory: Cancer Today-IARC<sup>4</sup>, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary WHO-UNICEF estimates<sup>5</sup>, CIA The World Factbook<sup>6</sup>